Fluconazole Capsule 150 mg

Adult dose

The route of administration should be determined according to the patient's clinical condition. Oral formulations are absorbed rapidly and almost completely; therefore, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. Vaginal candidiasis: Administer a single oral dose of 150 mg fluconazole. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this medicine is 400 mg once on the first day, followed from the next day by 200 mg once daily; the dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment should be determined according to clinical response and medical judgment. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this medicine is 400 mg once on the first day, followed from the next day by 200-400 mg once daily. The duration of treatment is determined by clinical and mycological response, but treatment should usually be given for at least 6 ~ 8 weeks. To prevent recurrence of cryptococcal meningitis in patients with AIDS, after the patient has completed primary treatment, administer 200 mg of this medicine once daily indefinitely. Prevention of fungal infections in immunocompromised patients at risk of fungal infection due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this medicine once daily, depending on the patient's risk of developing a fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as patients expected to have severe or prolonged neutropenia, as in bone marrow transplantation. In these patients, administer 400 mg starting 5-6 days before the anticipated onset of neutropenia and continue 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or higher. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until new, uninfected nails have grown). New fingernails usually take 3-6 months to grow, and toenails take approximately 6-12 months; growth rate may vary by individual and age. In some cases, the nails may remain damaged even after successful treatment with long-term administration. Dermatophyte infections, including athlete's foot (tinea pedis), tinea corporis, tinea cruris, and cutaneous candidiasis: The usual dose of this medicine is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks, depending on the course of the disease. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. Elderly patients: If renal function is normal, the usual adult dose may be administered. If renal impairment is present (creatinine clearance 50 mL/min or less), reduce the dose or extend the dosing interval. Patients with renal impairment: This medicine is excreted mainly in the urine unchanged. No dose adjustment is required for a single dose. If multiple doses are required, administer the usual dose only on the first day, then adjust the dose as follows from the next day. Creatinine clearance (mL/min) > 50: 100 % of the usual dose Creatinine clearance (mL/min) ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients on hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, administer a reduced dose according to creatinine clearance.

This medication should not be used by patients who have hypersensitivity to specific ingredients or are allergic to azole medications. Pregnant women or those who may become pregnant, as well as nursing mothers, should not take this medication. Additionally, certain medications may pose risks when taken with this drug, so it is essential to inform the healthcare provider of any currently taken medications. Patients with lactose intolerance or specific genetic metabolic disorders should not take this medication. Patients with renal or hepatic function issues should use this medication with caution, as there is a possibility of worsening liver function. Patients with heart diseases or electrolyte imbalances should be cautious when taking this medication due to the risk of heart problems, such as arrhythmias. This medication should be monitored through liver and kidney function tests, blood tests, etc. While on this medication, various side effects such as headache, abdominal pain, diarrhea, and rash may occur, so it is important to consult a doctor immediately if any unusual symptoms arise. Severe skin reactions or liver function abnormalities may occur, requiring careful monitoring. This medication has many drug interactions, so combinations with other medications must be discussed with healthcare professionals. Particularly, taking it with drugs that could affect the heart may be dangerous, thus it is essential to inform the doctor before taking. This medication should not be used during pregnancy, and women of childbearing potential should employ contraception during and for a period after taking this medication. Nursing mothers should also refrain from taking this medication. For children, it should only be used in specific cases as safety has not been established for those under 6 months old. Dizziness or seizures may occur while on this medication, so caution is needed when driving or operating machinery. In case of overdose, hallucinations or abnormal behavior may occur, and emergency treatment should be sought immediately.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, dysgeusia, tremor, vertigo, Torsade de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased alkaline phosphatase in the blood, cholestasis, jaundice, increased bilirubin, hepatotoxicity, hepatic failure, hepatocellular necrosis, hepatitis, hepatocyte damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, lethargy, weakness, fever, adrenal insufficiency, hallucinations, psychotic behavior

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should ideally be maintained between 1 to 30 degrees Celsius to preserve the medication’s effectiveness and prevent degradation.

Appearance

Capsule with a dark blue upper part and light blue lower part filled with white powder

Package unit

30 capsules/bottle